Related Experiment Video
Updated: Jun 28, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis
1Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. j-varga@northwestern.edu
Current Opinion in Rheumatology
|October 24, 2008
Summary
Transforming growth factor-beta (TGF-beta) therapies show promise for treating fibrotic diseases like systemic sclerosis. However, careful consideration of efficacy, safety, and patient selection is crucial for successful therapeutic application.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Transforming growth factor-beta (TGF-beta) is vital for tissue homeostasis.
- Dysregulated TGF-beta signaling contributes to fibrotic diseases.
- TGF-beta represents a key molecular target for therapeutic intervention.
Purpose of the Study:
- To review current strategies for inhibiting excessive TGF-beta function.
- To evaluate the potential of various anti-TGF-beta therapies.
- To discuss challenges and future directions in anti-TGF-beta treatment.
Main Methods:
- Review of RNA-based technologies, monoclonal antibodies, and small molecules targeting TGF-beta.
- Analysis of clinical trial data for TGF-beta inhibitors.
- Examination of preclinical studies on alphavbeta6 integrin antibodies.
- Assessment of small molecules inhibiting TGF-beta receptor kinase activity.
Main Results:
- Monoclonal antibodies targeting TGF-beta have shown disappointing clinical results.
- Antibodies to alphavbeta6 integrin demonstrate promise in preclinical models.
- Numerous small molecules inhibit TGF-beta receptor kinase activity; some existing drugs show anti-TGF-beta effects.
- Potential side effects include immune activation, hyperplasia, and impaired wound healing; autoimmunity is a concern.
Conclusions:
- Anti-TGF-beta therapies hold significant potential for treating systemic sclerosis.
- Addressing concerns regarding efficacy and safety is paramount.
- Identifying optimal patient candidates and biomarkers for safety and efficacy are critical future challenges.
Related Concept Videos
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...